Plasmology4

Within the framework of investment portfolio formation, ACP Global made a strategic investment in Plasmology4, Inc., the leader in non-thermal plasma technology for advanced healthcare solutions, which paves the way for a partnership of Plasmology4’s innovative products into ACP Global’s international distribution network, ensuring access and utilization of this breakthrough medical technology.

Plasmology4 is harnessing the 4th state of matter to improve the quality of patients’ lives worldwide. The Company has developed a platform technology known as Plaz4 which has several potential applications in the healthcare market. Plasmology4 is currently advancing its Plaz4 technology for the treatment of infected wounds, including multidrug-resistant bacteria such as MRSA.

The Company’s executive management team and Scientific Advisory Board are seasoned professionals and Key Opinion Leaders in the areas of biomedical device product development, intellectual property, plasma science and engineering, biomedical research, and healthcare systems and delivery.

Plasmology4 was awarded a federal grant under the Therapeutic Discovery Project Program. This program provided grants to small companies with a promising and important therapeutic technology.

Taking all factors into consideration, the decision to partner with Plasmology4 on the road to success was ultimate and immediate. We seem to share the same views and values, which is an important factor for our company when identifying new projects for investment.

ACP Global is hopeful that this technology will make a huge impact in the healthcare industry, and are very proud to be a part of this pivotal moment.